Wall Street analysts forecast that AstraZeneca plc (NYSE:AZN) will announce $6.33 billion in sales for the current quarter, according to Zacks. Two analysts have made estimates for AstraZeneca’s earnings. The highest sales estimate is $6.63 billion and the lowest is $6.02 billion. AstraZeneca posted sales of $5.82 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 8.8%. The business is scheduled to issue its next quarterly earnings report before the market opens on Thursday, July 30th.
On average, analysts expect that AstraZeneca will report full-year sales of $26.70 billion for the current fiscal year, with estimates ranging from $26.15 billion to $27.50 billion. For the next financial year, analysts anticipate that the company will report sales of $30.16 billion, with estimates ranging from $28.52 billion to $32.73 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for AstraZeneca.
AstraZeneca (NYSE:AZN) last released its earnings results on Wednesday, April 29th. The company reported $0.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.06. The company had revenue of $6.35 billion for the quarter, compared to analysts’ expectations of $5.95 billion. AstraZeneca had a return on equity of 33.97% and a net margin of 5.94%. The business’s revenue for the quarter was up 16.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.89 EPS.
Several brokerages have recently issued reports on AZN. SVB Leerink lifted their price target on AstraZeneca from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Friday, May 29th. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Monday, April 27th. UBS Group reiterated a “sell” rating on shares of AstraZeneca in a report on Thursday, June 4th. Cowen boosted their target price on AstraZeneca from $55.00 to $60.00 in a report on Wednesday, June 10th. Finally, Argus boosted their target price on AstraZeneca from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. AstraZeneca presently has an average rating of “Hold” and a consensus target price of $59.75.
Several hedge funds have recently modified their holdings of the company. Quadrant Capital Group LLC lifted its stake in shares of AstraZeneca by 11.6% during the fourth quarter. Quadrant Capital Group LLC now owns 34,837 shares of the company’s stock valued at $1,711,000 after acquiring an additional 3,621 shares during the period. First Trust Advisors LP acquired a new position in shares of AstraZeneca during the fourth quarter valued at $287,000. New York State Common Retirement Fund acquired a new position in AstraZeneca in the fourth quarter valued at about $226,000. Cetera Advisor Networks LLC lifted its stake in AstraZeneca by 6.0% in the fourth quarter. Cetera Advisor Networks LLC now owns 5,293 shares of the company’s stock valued at $259,000 after buying an additional 298 shares during the period. Finally, Quantbot Technologies LP acquired a new position in AstraZeneca in the fourth quarter valued at about $515,000. Institutional investors own 16.84% of the company’s stock.
Shares of AstraZeneca stock traded up $0.21 during trading on Thursday, hitting $52.91. 4,526,100 shares of the stock traded hands, compared to its average volume of 4,623,390. The stock has a market cap of $138.80 billion, a P/E ratio of 89.68, a PEG ratio of 1.57 and a beta of 0.57. The company has a debt-to-equity ratio of 1.32, a quick ratio of 0.57 and a current ratio of 0.75. AstraZeneca has a twelve month low of $36.15 and a twelve month high of $57.44. The company has a fifty day moving average price of $53.55 and a two-hundred day moving average price of $49.38.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What is a good dividend yield?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.